PubRank

Andrew R Branagan

Author PubWeight™ 23.40‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Clinicopathological definition of Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. Semin Oncol 2003 3.88
2 Polymorphisms in FcgammaRIIIA (CD16) receptor expression are associated with clinical response to rituximab in Waldenström's macroglobulinemia. J Clin Oncol 2005 1.91
3 Update on treatment recommendations from the Third International Workshop on Waldenstrom's macroglobulinemia. Blood 2006 1.51
4 Multicenter clinical trial of bortezomib in relapsed/refractory Waldenstrom's macroglobulinemia: results of WMCTG Trial 03-248. Clin Cancer Res 2007 1.33
5 Prognostic markers and criteria to initiate therapy in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. Semin Oncol 2003 1.33
6 Establishment of BCWM.1 cell line for Waldenström's macroglobulinemia with productive in vivo engraftment in SCID-hu mice. Exp Hematol 2007 1.26
7 Treatment recommendations in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. Semin Oncol 2003 1.13
8 Long-term outcomes to fludarabine and rituximab in Waldenström macroglobulinemia. Blood 2008 1.09
9 Genetic linkage of Fc gamma RIIa and Fc gamma RIIIa and implications for their use in predicting clinical responses to CD20-directed monoclonal antibody therapy. Clin Lymphoma Myeloma 2007 1.07
10 Clinical responses to sildenafil in Waldenstrom's macroglobulinemia. Clin Lymphoma 2004 1.07
11 Thalidomide and rituximab in Waldenstrom macroglobulinemia. Blood 2008 1.03
12 Lenalidomide and rituximab in Waldenstrom's macroglobulinemia. Clin Cancer Res 2009 1.00
13 Uniform response criteria in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. Semin Oncol 2003 0.96
14 CD27-CD70 interactions in the pathogenesis of Waldenstrom macroglobulinemia. Blood 2008 0.89
15 CD52 is expressed on human mast cells and is a potential therapeutic target in Waldenstrom's Macroglobulinemia and mast cell disorders. Clin Lymphoma Myeloma 2006 0.89
16 Clonal Immunoglobulin against Lysolipids in the Origin of Myeloma. N Engl J Med 2016 0.89
17 Hepatitis C viral infection is not associated with Waldenström's macroglobulinemia. Am J Hematol 2007 0.87
18 CD5, CD10, and CD23 expression in Waldenstrom's macroglobulinemia. Clin Lymphoma 2005 0.84
19 Novel agents in the treatment of Waldenström's macroglobulinemia. Clin Lymphoma Myeloma 2007 0.83